Abbreviations: AI, alkylindole; GBM, glioblastoma multiforme; i.p., intraperitoneal; LC-MS, liquid chromatography-mass spectrometry; MTD, maximal tolerated dose, MT, microtubule; PARP, poly ADP ribose polymerase; PK, pharmacokinetics. Further investigation in a syngeneic orthotopic mouse model of GBM shows that ST-11 activates caspase-3 in tumors to reduce tumor volume without overt toxicity. Thus, represents the first member of a new class of brain-penetrant antitubulin therapeutic agents.
INTRODUCTION
Gliomas comprise 80% of primary tumors in the central nervous system (1) and the most common subtype is glioblastoma multiforme (GBM, WHO grade IV astrocytoma). Patients diagnosed with GBM have a median overall survival of 14-15 months when treated with a standard regimen of surgery, radiation and the DNA intercalating agent temozolomide (Temodar ® ) (2) . Non-selective chemotherapeutics remain the sole drug treatment option for this patient population in large part because recent targeted therapies, such as gefitinib and bevacizumab that block EGFR and VEGF signaling, respectively, have fallen short of expectations (3) (4) (5) (6) . This realization has fueled a need for novel therapeutics to combat GBM
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3 through a different mechanism of action; however, the development of new GBM therapeutics is complicated by the necessity for efficient brain penetrance.
A recent study demonstrated that GBM cells are particularly sensitive to mitotic disruption when compared with matched nonmalignant cells (7) . This has led to the notion that therapies that perturb microtubule (MT) assembly may represent a promising strategy to manage this type of cancer. For example, recently approved antimitotic devices that generate electromagnetic fields known as tumor treatment fields (TTFields) and function by disrupting MTs show significant efficacy as novel GBM treatments (8, 9) . This result indicates that antitubulin agents are likely to show antineoplastic efficacy in patients diagnosed with GBM; however, the majority of antitubulin agents do not readily cross the blood-brain barrier [Reviewed in (10) ]. In fact, of the few brain-penetrant antitubulin agents, only 2, sagopilone (ZK-EPO) and the non-analgesic opioid noscapine, have been evaluated for glioma indications (11, 12) . However, sagopilone suffered from a lack of efficacy in clinical trials (13) , and noscapine required high doses to elicit an effect (12) . Irrespective of the limited success of currently available compounds, the susceptibility of GBM cells to mitotic perturbation holds considerable promise for the treatment of this type of cancer (7) . To this end, it is necessary to discover and develop novel brain-penetrant antitubulin agents with high therapeutic potential.
Our lab has recently developed a library of alkylindole (AI) compounds with the capacity to kill glioma cells in vitro (14, 15) . These compounds belong to the broader group of 2-aroylindole agents that inhibit tubulin polymerization by interacting with the colchicine binding site and are insensitive to multidrug resistance efflux pumps that can hinder brain penetrance (16) (17) (18) . Here, we used a combination of biochemical and cell biology approaches to demonstrate that the AI compound ST-11 arrests the cell cycle and kills glioma cells by directly acting on MTs. To determine the pharmacokinetics (PK) and in vivo efficacy of ST-11, we established a stable formulation of this compound in liposomes and developed a liquid
4 chromatography-mass spectrometry (LC-MS) method to quantify ST-11 in blood and brain.
Using these tools, we determined that ST-11 readily penetrates mouse brain after intraperitoneal (i.p.) injection and dose-dependently reduces tumor volume in a syngeneic GBM mouse model. Importantly, ST-11 does not produce overt toxicity in mice. Our study highlights the therapeutic potential of AI compounds as brain-penetrant antitubulin agents with antineoplastic activity in GBM.
MATERIALS & METHODS

See supplement for detailed methods
Chemicals
All chemicals and drugs were purchased from Sigma (St. Louis, MO) unless otherwise noted.
JWH-015, and JWH-200 were from Cayman Chemical (Ann Arbor, MI). JWH-120, JWH-148, and JWH-042 were a kind gift from John W. Huffman (Clemson University, Clemson, SC). ST compounds were synthesized in house as described (14, 15) . Z-DEVD-FMK was from Santa Cruz Biotechnology (Santa Cruz, CA). L-α-Phosphatidylcholine (EPC) was from Avanti Polar Lipids (Alabastar, AL). 1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol, sodium salt (DMPG) and N-(Carbonyl-methosypolyethyleneglycol-2000)-1,2-dimyristoyl-sn-glycero-3-phosphoethanolzmine, sodium salt (DMPE-mPEG2000) were from Corden Pharma (Plankstadt, Germany). Cell culture materials were purchased from Life Technologies (Thermo Fisher Scientific, Waltham, MA).
Cell culture
Cells were cultured in DMEM or RPMI containing 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C in a 5% CO 2 humidified atmosphere. DBT, T98G, U251, A172, and U87MG cells (ATCC, Manassas, VA) were authenticated by ATCC when purchased using
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human short tandem repeat analysis and maintained in culture for less than 6 months. BT74, MGG4 and MGG8 cells were a generous gift from Samuel Rabkin and Hiroaki Wakimoto (Massachusetts General Hospital and Harvard University, Boston, MA) and maintained as floating spheroid cultures in Neurobasal-A medium (19) . All spheroid cultures were maintained in ex vivo culture for less than 6 months and not authenticated [BT74 as GBM6 in (20) , MGG8/8 in (19) ]. Primary mouse neuron and astrocyte cultures were prepared as described (21, 22) in accordance with the Institutional Animal Care and Use Committee of the University of Washington.
Viability and proliferation
[ 3 H]-thymidine (5 µCi/ml, Perkin-Elmer, Waltham, MA) was added to cells 30 min after drug treatments and measured at the indicated times by adding 1M NaOH and quantifying radioactivity. WST-1 (Roche, Pleasanton, CA) was used to evaluate cell viability and was measured according to the manufacturer's protocol. For proliferation and cell death using trypan blue exclusion, cells were trypsinized and counted in the presence of trypan blue (1:10, Sigma).
Lysates and western blotting
Western blotting was performed as described previously (23) with the following primary antibodies: cleaved poly ADP ribose polymerase (1:1000, Asp214), cyclin B1 (1:1000, Val152), phospho-histone H3 (1:1000, Ser10), β-tubulin (1:1000), and activated caspase-3 (1:500) were all from Cell Signaling Technologies (Danvers, MA, USA); GAPDH (1:1000) was from Sigma.
MT assembly
MTs were polymerized and sheared in BRB80 (80 mM PIPES-KOH pH 6.85, 1 mM MgCl 2 , 1 mM EGTA) supplemented with 4% DMSO, 2 mM GTP, 1 mM DTT, 2.5 mM MgCl 2 and 60 µM ST-11 is a brain-penetrant antitubulin agent that kills GBM 6 bovine brain tubulin and added to paclitaxel (Taxol®), nocodazole, or ST-11 to a 1% final DMSO concentration. Details can be found in the Supplemental methods. Free tubulin from supernatants and pellets was separated on 4-12% polyacrylamide gels (Thermo-Fisher Scientific, Waltham, MA) and stained with Coomassie G-250. Peak intensities were quantified using ImageJ. Tubulin was purified in-house (24) .
Live cell imaging
Cells were transfected with EB3-GFP and RFP-CenpB to label assembling MTs and centromeres, respectively (25) . Movies of MT assembly were collected over 30 sec at 500 ms intervals 10 min after drug application (0.5 µM ST-11, 3 µM ST-11, or 1 µM nocodazole) on a Deltavision microscope system (Applied Precision, Issaquah, WA). Images were deconvolved using SoftWorx 5.0 (Applied Precision). MT assembly rates were scored in interphase cells using Fiji TrackMate (26) .
Immunocytochemistry
Cells were treated with ST-11 as indicated. Activated caspase-3, MTs, and centromeres were visualized using anti-activated caspase-3 (1:200, Abcam, Cambridge, MA), anti-DM1 alpha (1:500, Sigma), and human anti-centromere (1:100, ACA, Antibodies Inc., Davis, CA) primary antibodies, respectively. Representative images are presented as flat Z-projections (using ImageJ). Spindle profiles and multipolar spindles were scored by hand using a Nikon FX-A microscope (Tokyo, Japan).
Flow cytometry analysis
Cells were lysed in a DAPI-containing lysis solution (146 mM NaCl, 10 mM Tris-base pH 7.4, 2 mM CaCl 2 , 22 mM MgCl 2 , 0.05% BSA, 0.1% nonidet P-40, 10 µg/ml DAPI, 10% DMSO) or stained for PI and Annexin V using the Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit
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(Thermo Fisher Scientific) according to the manufacturer's protocol. 10,000 events were counted for each condition using an LSRII flow cytometer (BD Biosciences). Data were analyzed using FCS Express (v4 De Novo Software, Glendale, CA) equipped with the MultiCycle plugin. See Supplemental methods for details.
ST-11 nanoparticle formulation
The chemical parameters of ST-11 were determined using Chemicalize Beta (www.chemicalize.org). The likelihood of ST-11 brain penetration was estimated using the induction tree models outlined by (27) . EPC:DMPG:DMPE-mPEG2000 (9:1:0.5 m/m/m) nanoparticles containing ST-11 for in vivo studies were produced as described previously (28) .
Details can be found in the Supplemental methods.
Pilot safety studies
All animal experiments were conducted in accordance with the American Association for Accreditation of Laboratory Animal Care, and all procedures were approved by the University of Washington Institutional Animal Care and Use Committee. A 5-day dose-range finding study was performed following screening for maximum tolerated dose. CD1 mice received once daily intraperitoneal (i.p.) dosing with 15, 40, 80, 160 or 240 mg/kg ST-11, or the corresponding volume of liposome vehicle. Mice were monitored for signs of general distress, including ataxia, squinting, piloerection, hunching, bradykinesia and dyspnea. Additionally, mice were monitored for organ dysfunction and/or moribund state. Mice were then euthanized and organs were harvested for histopathological analysis by a board-certified veterinary pathologist (Dr.
Denny Liggitt) who was blinded to group assignment.
Tissue extraction and ST-11 quantification by LC-MS
Lipids were isolated from CD1 mouse blood and whole brain, and JWH-015 was used as an internal standard for quantification. Lipid composition was analyzed using a Waters Micromass paraformaldehyde, and whole brains were harvested.
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H&E and Immunohistochemistry (IHC)
Whole brains were stained as described previously (29), with the following primary antibodies:
anti-activated caspase-3 (1:200, Abcam) and anti-Iba-1 (1:1000, Abcam). For H&E staining, fixed brains were either sent to Histology Consultation Services (Everson, WA), or processed in-house using a standard method (5 sec in concentrated Mayer's hematoxylin and 60 sec in concentrated Eosin Y).
Tumor volume
Tumor volume was estimated by slab approximation (30) . Details can be found in Supplemental methods. Large numbers of microglia invade GBM tumor masses [Reviewed in (31) ] ( Figure   S2 ). We calculated the percentage of infiltrating microglia in each tumor using semi-
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quantitative IHC as described previously (29) and subtracted this value from the calculated tumor volume to obtain the adjusted tumor volume.
Statistical Analysis
GraphPad Prism (v5.01, La Jolla, CA) was used for statistical analysis. Data are presented as the mean ± SEM, and statistical significance was determined using Student's t-test, a one-way ANOVA followed by a Dunnett's or Tukey post-hoc test, or a two-way ANOVA followed by a
Bonferroni post-hoc test.
RESULTS
ST-11 inhibits proliferation and kills GBM cells in vitro
A library of 10 AI analogues was screened for activity on the human GBM cell line T98G (Table   S1 ). One compound, named ST-11, exhibited a combination of properties requisite for further mechanistic and in vivo analyses: it reduced T98G cell number with the highest potency and efficacy, and it encompasses the basic chemical scaffold of the series (colloquially termed the ST compound library) ( Figure 1A , Table S1 ). Thus, ST-11 was selected for further screening on additional human GBM cell lines, including 3 adherent cell lines (U251, A172 and U87MG cells) and 3 stem cell lines (BT74, MGG4 and MGG8) (32) . ST-11 reduced cell number in all of the GBM lines tested when applied at micromolar concentrations (EC 50 from 2.4 -8.6 µM, maximal efficacy from 51 -96%) ( Table 1) . A vital and desired feature of any new antineoplastic drug is a favorable therapeutic index, which is related to the preferential activity of the compound for tumor cells. Thus, we tested the antineoplastic activity of ST-11 on malignant and nonmalignant mouse cells. ST-11 killed mouse DBT glioma cells with a potency and efficacy similar to T98G cells (EC 50 = 2.5 µM, maximal efficacy = 60.7%). Notably, this compound did not affect the viability of primary mouse astrocytes or neurons ( Figure 1B) . Therefore, ST-11
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preferentially targets a variety of GBM cell lines, including glioma stem cells, which tend to be refractive to therapy (33, 34) .
A loss of cell number can result from reductions in cell proliferation and/or increases in cell death. In order to delineate between both outcomes, we initially determined if ST-11
reduces cell viability using a trypan blue exclusion assay. ST-11 dose-dependently increased the percentage of trypan blue-positive dead cells with a potency and efficacy similar to what was detected using WST-1 (WST-1 EC 50 = 2.5 µM, maximal efficacy = 66%; trypan blue EC 50 = 4.3 µM, maximal efficacy = 68%, WST-1 EC 50 = 2.5 µM, maximal efficacy = 66%) (Table S1, Figure 1C ). We ascertained that ST-11 reduces cell proliferation using 2 independent approaches. First, we measured the dose-dependent effects of ST-11 on Second, we monitored the time-dependent effects of ST-11 action on the accumulation of 2 mitotic markers: cyclin-B1 and phospho-histone H3. Application of ST-11 led to an increase in both cyclin-B1 and phospho-histone H3 levels ( Figure 1E and 1F) . Thus, we propose that ST-11 reduces GBM cell number by arresting cells in mitosis and subsequently killing them.
ST-11 arrests cells in prometaphase by directly targeting MTs
To further confirm our hypothesis that ST-11 arrests GBM cells in mitosis 
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triggering the spindle assembly checkpoint [reviewed in (35, 36) ]. In line with this observation, we also noted that ST-11 both dose-dependently increased the proportion of cells with multipolar spindles (Figure 2C and S3D) and induced severe defects in chromosomal biorientation ( Figure 2D ).
Improper spindle assembly can be attributed to defects in MT dynamics and polymerization, and 2-aroylindole agents are known to directly depolymerize MTs (16, 17, 37, 38) . Therefore, we used 3 approaches to determine whether ST-11 was acting directly on MTs.
First, we used a cell-free assay with purified tubulin to assess the partitioning of MT dimers and polymer. As expected, the MT destabilizing agent nocodazole triggered an increase the free tubulin ( Figure 3A ). Conversely, a decrease in free tubulin levels was observed upon addition of the MT stabilizing agent paclitaxel ( Figure 3A ). Similar to nocodazole, ST-11 dose-dependently increased the level of free tubulin, which corresponds to MT disassembly ( Figure 3A) . Thus, ST-11 destabilizes MTs in a cell-free system containing purified MTs, implying that it directly acts on tubulin. The EC 50 of ST-11 on MT destabilization (EC 50 = 3.7 µM) is similar to its EC 50 on T98G and DBT cell viability, indicating MTs may be the direct molecular target of ST-11 involved in its antineoplastic effect. Second, we assessed whether ST-11 affected MT polymer levels in T98G cells in vitro. MTs were significantly less abundant in T98G cells treated with ST-11, demonstrating that this compound directly acts on MTs in cells ( Figure 3B ). Lastly, using live cell imaging of EB3-GFP on assembling MTs in T98G cells, we found that sub-micromolar concentrations of ST-11 (0.5 µM) decreased the MT assembly rate by 32% within 10 min of treatment ( Figure 3C and 3D, Movies S1 and S2). Importantly, the effects of ST-11 on MT assembly were reversible by 24 hrs after drug removal ( Figure S4A ). Nocodazole and ST-11 both exhibit robust MT depolymerizing activity on purified tubulin ( Figure 3A) . To compare the activity of these compounds on live T98G cells, we selected concentrations of ST-11 (3 µM) and nocodazole (1 µM) that exhibit comparable MT destabilizing activity on purified tubulin ( Figure 3A ). We noted that nocodazole abolished all assembling MTs in live T98G cells by 15 min ( Figure S4B ). In contrast, MTs continued to assemble after ST-11 treatment (3 µM) ( Figure   S4B ) albeit more slowly. Thus, while ST-11 has a significant effect on cell cycle arrest at this concentration ( Figure 2B ), it does not abolish all dynamic MTs in interphase cells compared with nocodazole. Together, these results demonstrate that ST-11 directly acts on MTs to reduce MT assembly, leading to mitotic spindle defects and prometaphase arrest in GBM cells.
ST-11 activates caspase-3-dependent apoptosis
Antitubulin agents often promote caspase-dependent apoptosis (39) . Therefore, we sought to determine whether ST-11 activated apoptosis in GBM cells in vitro. ST-11 induced caspase-3 activation in both T98G and DBT cells as early as 2-6 hrs after treatment ( Figure 4A and S3E). To compare the in vitro efficacy of ST-11 with other antitubulin agents, we measured the time-dependent effects of ST-11, paclitaxel and nocodazole on T98G cell number using WST-1. By 12 hrs, all 3 compounds had reduced cell number by 10-15%. However, by 72 hrs, paclitaxel was inactive, whereas cell number was reduced by 34% with nocodazole and by 48% with ST-11 ( Figure 4E ). Notably, paclitaxel is known to have reduced activity in T98G cells due to their high expression of multidrug resistance (MDR) efflux pumps, such as MDR-1 (40).
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In contrast, paclitaxel reduced the viability of MDA-MB-231 breast cancer cells used as a positive control by 72 hrs ( Figure S6 ). This finding underscores the ability of ST-11 to retain efficacy in a cell line that expresses high levels of MDR pumps, a feature maintained by other 2-aroylindole compounds (17, 41) . ST-11 was therefore more effective at reducing cell number than 2 antitubulin compounds, one of which (paclitaxel) is widely used in the clinic as an antineoplastic drug. These findings suggest that further research into the in vivo safety and efficacy of ST-11 is warranted.
Solubility and safety of ST-11 in vivo
Because ST-11 does not adversely affect the viability non-malignant cells in vitro, we sought to study its safety and efficacy in vivo. We first assessed the maximal tolerated dose (MTD) and 
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14 be well tolerated. Additionally, tissue damage was assessed using H&E staining of 6 principal organs (heart, liver, kidney, lungs, spleen and brain). No signs of tissue injury were observed in any organ harvested from any ST-11 dosage group. However, we noted a prominence of slightly foamy macrophages in the marginal zone of the spleen of mice treated with both 240 mg/kg ST-11 and the matched liposome-only control. This finding indicates that the large amount of liposomes injected in this condition induced a high rate of liposome phagocytosis in a manner that was independent of ST-11 (data not shown). This pilot safety study indicates that ST-11 is well tolerated at high doses and does not produce overt toxic effects when administered daily over a wide dose range.
Pharmacokinetic profile of ST-11
A limiting factor of the use of many antitubulin agents to treat GBM is their inability to cross the blood-brain barrier [Reviewed in (10)]. Therefore, we used predictive models to determine the likelihood that ST-11 is brain-penetrant. Based on 2 decision tree induction models described in (27) , ST-11 is predicted to cross the blood-brain barrier (LogP = 5.81, rotatable bonds = 3, and polar surface area = 22). To confirm our predictions, we established the PK profile of ST-11 in healthy mice to evaluate whether this compound reaches the brain at concentrations that could produce antineoplastic activity (i.e. above its EC 50 for killing GBM cells in culture). We developed an LC-MS method to quantify ST-11 in biological matrices using a related compound, JWH-015, as an internal standard (see chemical structure in Table S1 ). Both compounds eluted at ~2.8 min ( Figure 5A ) and were independently detected with base peaks Figure 5D ). The limit of detection was 100 fg and the limit of quantitation was
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3 pg (error <10%). Thus, our newly developed method allows for the reliable and precise quantification of ST-11 from 0.1 to 1 ng in samples from mouse blood serum and brain tissue.
To establish the PK profile of ST-11, mice were treated with ST-11 (40 Figure 6B ). Importantly, we detected a dose-dependent increase in caspase-3 activation, nuclear condensation and cellular loss within the tumor mass ( Figure 6C ). Collectively, these results indicate that i.p. administration of ST-11 dose-
ST-11 induces apoptosis in orthotopic DBT tumors and reduces tumor volume
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dependently activates apoptosis and reduces the volume of orthotopically implanted DBT tumors.
DISCUSSION
In this study, we describe the pharmacology and mechanism of action of ST-11, a new AI compound that destabilizes MTs. This compound displays 3 properties that are requisite for treating GBMs: 1) the ability to cross the blood-brain barrier, 2) preferential selectivity for killing GBM cells and 3) a favorable safety profile when administered at doses above its therapeutic efficacy. Our study not only provides a solid foundation for further chemical optimization of this compound but also launches the pharmacological and biological characterization of this new class of brain-penetrant antitubulin agents. Accordingly, ST-11 and future derivatives may prove to be efficacious for the treatment of brain cancers such as GBM, which remain both one of the most devastating and therapeutically intractable forms of cancer.
ST-11 reduces GBM cell number by reducing both proliferation and viability.
Mechanistically, we have discovered that, similar to other 2-aroylindoles, this compound acts directly on MTs to reduce their assembly. The EC 50 s of the effects of ST-11 on MT destabilization in a cell-free assay and GBM cell viability are comparable. Taken together, these findings infer that tubulin is likely the primary target of this compound. Consistent with this result, ST-11 reduced the level of MT polymer and, at lower concentrations, the rate of assembling MTs. In living cells, MTs rapidly interconvert between assembly and disassembly.
This dynamic action is essential for the proper spindle assembly, chromosome attachment and segregation during mitosis (43) . Accordingly, we concluded that ST-11 suppressed MT dynamics in a manner that leads to aberrant spindle formation, improper alignment of chromosomes and cell cycle arrest in a prometaphase-like configuration. This effect is consistent with mitotic checkpoint arrest produced by the MT destabilizing activity of this compound.
Several important features distinguish ST-11 from nocodazole, which, similarly to 2-aroylindoles, directly interacts with the colchicine binding site. ST-11 and nocodazole exhibit different effects on MT dynamics in live T98G cells at concentrations that promote similar levels of MT depolymerization in a cell-free system. Nocodazole rapidly abolishes dynamic MTs whereas ST-11 leaves them intact. Like nocodazole, the effects of ST-11 on suppression of MT dynamics are fully reversible within 24 hrs. These findings are significant for 2 reasons.
First, the reversibility of this compound might limit toxicity, which is notable from a therapeutic standpoint. Irreversible MT destabilizing compounds, such as colchicine, often have a challenging therapeutic index and their clinical use can be hindered by toxicity (36) . Second, while ST-11 potently arrests cells in mitosis, its effects on interphase MT dynamics appear to be less severe. Likewise, this property may limit the clinical toxicity of this compound toward non-dividing cells, especially neuronal cells.
Drugs that disrupt MT dynamics are commonly prescribed therapeutics as they both reduce tumor cell proliferation and trigger apoptosis (36, 39) . Our finding that ST-11 kills GBM cells through the activation of caspase-3-dependent apoptosis is evidenced by caspase-3 and PARP cleavage, morphological changes, and increases in Annexin V/PI staining. Further support for this postulate is provided from our investigation of ST-11 on T98G cells where induction of apoptosis was ablated upon pretreatment with the caspase-3 inhibitor Z-DEVD-FMK. Therefore, we conclude that the principle mechanism of action of ST-11 is to directly suppress MT assembly, which leads to defects in mitotic spindle formation and chromosome attachment. This response is known to trigger mitotic checkpoint arrest and ultimately render glioma cells susceptible to apoptotic cell death [reviewed in (36) ].
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A recent study designed to identify novel therapeutic targets for the treatment of GBM that do not adversely affect healthy brain cells revealed that this type of cancer is particularly sensitive to mitotic disruption (7). Other investigators have examined the efficacy and potency of indole-containing compounds on MT disruption and tumor reduction using different cancer models (16, 17, 37) . For example, the antitubulin agent BPR0L075 effectively reduces tumor size in flank xenograft models of gastric and cervical carcinomas (17) . Importantly, our studies suggest that ST-11 has increased therapeutic potential over other classical antitubulin compounds. Specifically, it has a higher efficacy and more lasting effect than either paclitaxel or nocodazole on the viability of GBM cells in vitro. Thus, as a novel brain-penetrant compound, ST-11 underscores the therapeutic potential of antitubulin agents for the treatment of GBM.
Another feature of our study was the establishment of ST-11 brain permeability. We 
